Navigation Links
Increasing Focus on Customization of Healthcare Drives the Market for Personalized Medicine, According to a Soon to be Released Report by Global Industry Analysts, Inc.

San Jose, California (PRWEB) December 05, 2013

Follow us on LinkedIn – GIA invites senior industry executives, domain experts, technologists and market strategists to participate in a comprehensive global research initiative studying the “Personalized Medicine” markets. The study will examine key drivers and trends impacting the market such as development of new cutting edge prognostic tools to predict the outcome of drug therapies; development of biomarker detection technologies; growing focus on accurate treatment decisions to reduce healthcare costs and improve quality of healthcare services; expanding applications in cancer treatment; regulatory and reimbursement issues, and increased collaboration and partnerships across the personalized medicine continuum comprising of therapeutic companies, diagnostic companies, academic institutions, life sciences companies, healthcare IT companies and health insurance companies, among others.

Defined as a drug administration model based on molecular analysis of a patient’s unique genetic profile, Personalized Medicine is growing in popularity against a backdrop of growing focus on healthcare customization. A disruptive force in the healthcare system, personalized medicine is expected to create a rich mixture of opportunities and challenges for existing and emerging new market participants. The complexity of developing personalized medicine is resulting in pharma companies focusing on maintaining long-term synergistic partnerships with diagnostics companies. Development of effective personalized medicine is currently limited by the need to develop a vast base of quantitative biological data related to disease conditions. This challenge remains magnified in case of heterogeneous diseases like cancer wherein tumor phenotypes vary significantly from person to person impacting disease outcomes, and response to therapies. Regulatory and reimbursement issues flaunt the potential to influence fortunes in the market as it moves from discovery to development to the commercialization stage.

Pharma majors are currently facing patent expiries of blockbuster drugs and falling ROIs on R&D investments, as a result of the political move to cap spiraling healthcare costs by limiting the market exclusivity period. The scenario is throwing the focus squarely on personalized medicine as a new business diversification strategy. Personalized medicine offers companies protection against generic competition since targeted therapies are difficult to replicate by generic drug manufacturers, unlike conventional blockbuster drugs. In addition, against the backdrop of current healthcare cost rationing measures that include reductions in reimbursements, personalized medicine given its ability to enhance patient outcomes can actually help companies negotiate higher and wider reimbursement coverage from governments and private payors. All of these factors are expected to support increased R&D investments in the development of personalized medicine in the coming years.

Given the dire need to migrate from non-targeted chemo-therapeutic based approaches to molecularly targeted therapy, the field of oncology offers immediate commercial opportunities for personalized medicine. The study estimates Personalized Medicine to be a multi-million dollar market worldwide, while more precise market-size and growth projections will be made available during the 2nd stage of report preparation, and data analysis.

The research and analyses will be released shortly in the form of a comprehensive research report. The report by design will attempt to provide exhaustive analysis, data, trends, market share, market size, statistics, forecasts and competitive intelligence. The report is modeled to offer precise and unbiased, actionable market insights including in-depth segmentation of market sub-sectors, demand estimates and projections and analysis of trends in each of the sectors, identification of leading players, and the competitive structure, among others.

Developed for Drug Developers, Strategic Planners, Business Development Executives, Management Consultants, Investment Bankers, Consulting Firms, Marketing & Sales Executives, C-Level Decision Makers, Market Strategists and Technology Domain Experts, the report helps identify the biggest opportunities in this space and offers accurate latent demand forecasting that empowers quantitative decision making among existing market players and new entrants.

For more details about how you can participate, please click here.

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.

Follow us on LinkedIn.

Global Industry Analysts, Inc.
Telephone: 408-528-9966
Fax: 408-528-9977
Email: press(at)StrategyR(dot)com
Web Site:


Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. In The Face Of Increasing Healthcare Spend And High-Cost Targeted Treatment, Market Access Barriers Continue To Rise For Targeted Oncology Drugs
2. Increasing Need for Supply of High-Quality Water Drives Growth in the Water Analysis Instrumentation Market, According to New Report by Global Industry Analysts, Inc.
3. SynteractHCR Increasing Participation in Industry Events in US and Europe
4. Report Finds Healthcare Sales Job Openings are Down but Increasing
5. Growing Awareness & Increasing Number of Indications Drive the Global Intravenous Immunoglobulin Market, According to a New Report by Global Industry Analysts, Inc.
6. Frost & Sullivan Recognizes Sciformixs Continued Growth in the Increasingly Complex Pharmaceutical KPO Market
7. Probiotic Action Shares Insight on What New Foods Are Increasing the Strength of Bad Bacteria
8. Gastroenterologists Indicate They Are Increasingly Using Biologics to Treat Patients with Crohns Disease in Remission than They Were One Year Ago, According to a Recent BioTrends Report
9. Frost & Sullivan: Modest Growth Projected in the U.S. Breast Imaging Systems Market Amidst Increasing Breast Cancer Prevalence
10. Sangui and SastoMed Complement Licensing Agreement in View of Increasing Sales Success
11. Big Pharma and Universities Increasingly Work to Advance Life Science Knowledge by Forming Strategic Partnerships, Public-Private Partnerships, and Open Innovation Programs: Pharmaceutical Research Collaborations Summit
Post Your Comments:
(Date:12/1/2015)... 1, 2015 Frost & Sullivan is ... program addresses ways companies can innovate and transform ... --> ... --> ... well as the disrupting factors altering the industry, ...
(Date:12/1/2015)... DUBLIN , Dec. 01, 2015 /PRNewswire/ ... announced the addition of the "2016 ... Sales Forecasts, Innovative Technologies, Competitive Strategies, Opportunities ... report to their offering. --> ... the "2016 Europe Cell Surface Markers: ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... announces that its best selling system laboratory animal colony management software solution, ezColony®, ... without investing in on-site IT resources., , Many organizations ...
(Date:12/1/2015)... SUNNYVALE, Calif. , Dec. 1, 2015 ... part of its participation at the Piper Jaffray Healthcare ... later this morning, the Company is reaffirming its outlook ... guidance for 2016, in addition to discussing longer term ... Chairman and Chief Executive Officer.  "We continue to be ...
Breaking Biology Technology:
(Date:11/18/2015)... ALBANY, New York , November 18, 2015 /PRNewswire/ ... Transparency Market Research has published a new market report ... Share, Growth, Trends, and Forecast, 2015 - 2021. According to ... bn in 2014 and is anticipated to reach US$29.1 ... 2015 to 2021. North America ...
(Date:11/17/2015)... LIVERMORE, Calif. , Nov. 17, 2015  Vigilant ... has joined its Board of Directors. ... Vigilant,s Board after recently retiring from the partnership at ... owning 107 companies with over $140 Billion in revenue.  ... performance improvement across all the TPG companies, from 1997 ...
(Date:11/12/2015)... 2015  A golden retriever that stayed healthy despite ... has provided a new lead for treating this muscle-wasting ... Institute of MIT and Harvard and the University of ... Cell, pinpoints a protective gene that ... effects. The Boston Children,s lab of Lou Kunkel ...
Breaking Biology News(10 mins):